Products

Sanhuangweng Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    • Product Name: Sanhuangweng Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions
    • Factroy Site: Yudu County, Ganzhou, Jiangxi, China
    • Price Inquiry: sales10@sinochem-nanjing.com
    • Manufacturer: Ascent Petrochem Holdings Co., Limited
    • CONTACT NOW
    VTB
    Specifications
    HS Code 184830
    Product Name Sanhuangweng Oral Solution Veterinary Grade API
    Active Ingredient Source Standardized extracts from Coptis chinensis, Scutellaria baicalensis, Phellodendron amurense and Pulsatilla chinensis
    Marker Compounds Berberine, baicalin, phellodendrine and anemoside B4
    Physical Appearance Brownish-yellow to dark brown liquid or dried powder depending on downstream processing
    Solubility Freely soluble in water and dilute ethanol; miscible in aqueous veterinary formulations
    Ph pH of a 1% aqueous solution is approximately 4.5 to 6.5
    Functional Use Antibacterial, antipyretic, anti-inflammatory and antidiarreal active pharmaceutical ingredient for veterinary medicine
    Target Species Pigs, cattle, sheep, chickens, ducks, geese and rabbits
    Indications Bacterial enteritis, gastroenteritis, colibacillosis, Escherichia coli infection and supportive treatment for respiratory and digestive tract infections
    Finished Dosage Forms Suitable for manufacturing tablets, injections, capsules, powders, granules, premixes and oral solutions
    Stability Stable under normal veterinary drug manufacturing conditions; avoid high humidity, direct sunlight and repeated freeze-thaw cycles
    Storage Conditions Seal tightly and store in a cool, dry, well-ventilated area away from light
    Shelf Life 24 months from date of manufacture when stored in original unopened packaging
    Quality Grade Veterinary grade; for animal use only

    As an accredited Sanhuangweng Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing Packaged as 25 kg net in sealed double polyethylene-lined drums with tamper-proof cap, labeled Sanhuangweng Oral Solution Veterinary Grade API.
    Container Loading (20′ FCL) 20′ FCL container loading: Sanhuangweng Oral Solution Veterinary Grade API for tablets, injections, capsules, powders, granules, premix, solutions.
    Shipping Ship in sealed, moisture-proof packaging suitable for powders or solutions, with temperature control as required for stability. Include Material Safety Data Sheet, Certificate of Analysis, and customs documentation declaring “Veterinary Pharmaceutical API – For Manufacturing Use Only.” Observe all applicable import/export and dangerous goods regulations.
    Storage Store in a tightly sealed, moisture-proof container in a cool, dry, well-ventilated area. Protect from direct sunlight, excessive heat, and humidity. Maintain storage temperature not exceeding 25°C unless otherwise specified. Keep away from strong oxidizing agents and incompatible materials. Ensure container remains properly closed after use. Keep out of reach of children and animals.
    Shelf Life The shelf life of Sanhuangweng Oral Solution Veterinary Grade API is 24 months when stored sealed, dry, and protected from light.
    Application of Sanhuangweng Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions

    On broiler farms with high-capacity nipple drinker lines, the concentrated liquid API is normally administered through a proportioning medicator. The incoming barrel is checked for baicalin content, and the dilution factor is set only after the certificate of analysis is reviewed. At a baicalin assay of 3.0 mg/mL, the working concentration in drinking water is 1.0 mL/L to 2.0 mL/L. The stock solution is prepared at 1:50 v/v in a separate tank because direct dosing from the barrel causes pump pulsation and uneven delivery. Free chlorine above 2.0 ppm oxidizes berberine-type alkaloids; the water is therefore held in a carbon-filtered buffer tank until residual chlorine falls below 0.3 ppm. The pH is maintained between 5.8 and 6.5 with a citric acid-sodium citrate buffer. At pH below 4.2, insoluble precipitates form and block nipple drinkers. The prepared solution is discarded after 8 h when ambient temperature exceeds 28°C. The terminal product is a drinking-water medication for flocks; each batch must be released with a microbial limit of aerobic plate count below 1000 CFU/mL and absence of Salmonella in 10 mL. EU Regulation 2019/6 requires that the target species and withdrawal period be stated in the marketing authorisation.

    What Compression Parameters Prevent Lamination in Herbal Extract Tablets?

    Tablet compression of dry-sprayed Sanhuangweng liquid extract is constrained by the plastic deformation behaviour of the dried solids. When the liquid API is spray-dried onto a maltodextrin-starch carrier to 25% w/w dry solids, the resultant powder is passed through a 0.8 mm screen before dry blending. Direct compression is restricted to an extract load below 20% w/w; above this level, tablet hardness falls and capping increases. Wet granulation with 2.5% w/w hydroxypropyl methylcellulose solution is preferred for extract loads of 20–30% w/w. The granulation is dried to residual moisture below 2.5% w/w. Croscarmellose sodium at 3.0% w/w is added extragranularly to obtain disintegration below 30 s at 37°C. A 16-station rotary press with B-tooling operates between 20 kN and 35 kN. Production batches above 40 kN show lamination. Target tablet hardness of 60–90 N gives friability below 0.8% after 100 revolutions per USP <1216>. Dissolution testing is performed with 900 mL of pH 6.8 phosphate buffer at 50 rpm using USP <711> apparatus II; not less than 75% of labeled baicalin releases within 45 min. The terminal product is an oral tablet for swine, with the dose calculated from bodyweight and the labeled extract quantity.

    Injectable formulations built around a herbal decoction-type extract introduce constraints that tablet and premix processes do not encounter. The liquid API as supplied is not sterile and may contain plant-derived polysaccharides, tannins, and pyrogens. Aseptic filtration is the only reliable sterilisation method when the filtered solution has a turbidity below 5 NTU. The extract is first cooled to 2–8°C and held for 12 h to allow suspended mucilage to settle. It is then passed through a 0.45 µm polyethersulfone filter and subsequently through a 0.22 µm membrane under a differential pressure not exceeding 1.0 bar. For isotonicity, sodium chloride is added to 0.9% w/v; pH is adjusted to 5.5–6.5 with diluted hydrochloric acid or sodium hydroxide. Terminal steam sterilisation at 121°C for 15 min is not recommended for this configuration because published stability data for baicalin and berberine under saturated steam are limited, and brown discolouration is observed in some development batches. The finished solution is filled into 10 mL neutral glass vials under nitrogen. Sterility is tested according to USP <71>, bacterial endotoxins according to USP <85>, and sub-visible particles according to USP <788>.

    Injectable release test matrix for liquid extract presentations
    ParameterAcceptance criterionStandard
    SterilityNo growth after 14 daysUSP <71>
    Bacterial endotoxins< 0.5 EU/mg extract dry matterUSP <85>
    Sub-visible particles ≥ 10 µm≤ 6000 per containerUSP <788>
    Sub-visible particles ≥ 25 µm≤ 600 per containerUSP <788>
    pH5.5–6.5Ph. Eur. 2.2.3
    Marker content90.0–110.0% of label for baicalin and berberineHPLC with Ph. Eur. 2.2.29

    Fluidised-bed granulation yields a low-dust premix for in-feed medication.

    A top-spray fluidised bed granulator is charged with 40 kg of a mixed carrier composed of corncob meal and lactose monohydrate in a 4:1 ratio. The liquid API is sprayed at an inlet air temperature of 60–70°C and an outlet air temperature of 35–40°C. The spray rate is maintained between 200 g/min and 300 g/min; higher rates lead to local overwetting and agglomerate formation. The target liquid load is 10% w/w on dry carrier, giving a free-flowing premix that passes through a 0.8 mm sieve. A 5% w/w aqueous polyvinylpyrrolidone K30 solution serves as binder; the total binder volume is divided into three equal portions and added at 10 min intervals to avoid crusting on the filter bags. The granulated premix is dried to final moisture below 3.5% w/w. Mixing uniformity in a double-ribbon blender is tested by near-infrared spectroscopy; the coefficient of variation for baicalin must remain below 5% in 10 sampling points. The terminal product is an in-feed premix for swine and poultry, incorporated at 5–10 kg/t of complete feed depending on the registered dosage. The premix must be released under EU Regulation 2019/6 for medicated feed or under local 21 CFR 558.5 if intended for US medicated feed applications.

    Capsule filling limits and hygroscopicity thresholds for companion-animal oral use.

    Hard gelatin capsule filling of the spray-dried extract is limited by tap density and moisture sensitivity. The dried powder is milled to a particle size below 0.25 mm and blended with 1% w/w colloidal silicon dioxide to improve flow. The tap density is measured according to USP <616>; target values between 0.45 g/mL and 0.60 g/mL allow reproducible filling on a dosator-type capsule machine. Capsule size 0 is chosen for unit doses up to 350 mg; size 1 is used for lower doses. The powder moisture is held between 3.0% w/w and 4.0% w/w because higher moisture causes gelatin crosslinking and delayed disintegration. Disintegration is tested in water at 37°C with discs according to USP <701>. The finished capsules are tested for uniformity of dosage units according to USP <905>. The terminal product is an oral capsule for cats and dogs under veterinary prescription.

    Ruminant oral drench formulations require a higher buffering capacity than poultry drinking water because rumen-reticulum pH is acidic. The drench is prepared by diluting the liquid API to 20% v/v in a vehicle containing 0.5% w/v sodium carboxymethylcellulose and 0.1% w/v potassium sorbate. The viscosity target is 150–300 mPa·s at 25°C to permit passage through a standard drenching nozzle without dripping. Propylene glycol is included at 10% v/v as a co-solvent and mastication-safe carrier. The buffer system uses sodium citrate and citric acid to hold pH between 5.5 and 6.5; this range prevents precipitation of berberine alkaloids during storage at 5°C. Calves, lambs, and kids receive the drench by oral syringe; the dose volume is calculated from the labeled marker content and the target daily intake per kilogram of bodyweight. The terminal product is a viscous oral drench for ruminants, packaged in amber high-density polyethylene bottles.

    When pellet feed temperature exceeds 75°C, the carrier-protected powder is selected over the unprocessed liquid.

    Thermal exposure during feed pelleting is the main process conflict for this liquid API. Unprotected liquid extract added to the mixer before pelleting degrades sharply when conditioned meal temperature exceeds 75°C; baicalin recovery can fall by more than 15% within 30 min at 85°C. The carrier-protected powder is therefore used for pelleted feed. The powder is prepared by adsorbing the liquid API onto a calcium carbonate-silica blend at 15% w/w; the adsorbent mass is chosen to maintain a free-flowing state. The powder is introduced post-pelleting through a rotary feeder if the pellet die emits pellets above 80°C, or pre-pelleting when conditioning time is below 10 s. The final feed concentration is adjusted to deliver 1.0–2.0 L of original liquid API per tonne of complete feed. Feed homogeneity is confirmed by tracer studies using riboflavin; the coefficient of variation across 12 production samples must remain below 5%. Feed mills producing this product in the EU fall under Regulation EC 183/2005 and EU 2019/4 for medicated feed. The terminal product is a pelleted complete feed or top-dressed premix for food-producing animals.

    Free Quote

    Competitive Sanhuangweng Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please contact us at +8618963613625 or mail to sales10@sinochem-nanjing.com.

    We will respond to you as soon as possible.

    Tel: +8618963613625

    Email: sales10@sinochem-nanjing.com

    Inquiry

    Get Free Quote of Ascent Petrochem Holdings Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction

    Sanhuangweng Oral Solution Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is released as a concentrated aqueous multi-component botanical extract intended for further pharmaceutical processing. The material is not a finished veterinary medicinal product and is not intended for direct administration without validated dilution, adsorption, or carrier loading. Release is controlled by a supplier-specific model code that does not replace a national registration dossier; no harmonized VICH monograph assigns a fixed assay, so the specification set must be cross-referenced to the finished-product authorization. Typical release categories include appearance, odor, pH, relative density, total solids, water content, residue on ignition, heavy metals, arsenic, residual solvent profile, microbial enumeration, and marker compound content. The native liquid falls within a conventional concentrated extract range with total solids commonly between 25 g/100 g and 35 g/100 g, relative density between 1.05 and 1.15, and pH between 4.5 and 6.5. Exact marketed limits are batch-specific; published data for a universal specification are limited.

    What Distinguishes a Multi-Component Botanical API from a Single-Entity Synthetic Veterinary Active?

    The product is not a single molecular entity; therefore its quality cannot be expressed solely as percentage purity. Control is based on a marker window, chromatographic fingerprint area ratios, total extractable matter, and contaminant profiles. A single-entity synthetic active such as florfenicol or sulfadiazine sodium is assayed as a defined percentage of label claim on the dried basis, whereas the botanical API depends on the constancy of multiple markers, the extraction ratio, and the preservation of the native component distribution. This introduces broader batch-to-batch variance but also provides a multi-component profile that is absent from purified compounds. The liquid concentrate is dark, bulkier, and more hygroscopic than a white crystalline powder. These differences dictate downstream equipment selection; direct compression is not feasible from the native liquid, while a synthetic crystalline active is generally transferred as a dry powder without an intermediate adsorption step.

    Comparative control attributes for the botanical concentrate and a single-entity synthetic veterinary API
    Control attributeSanhuangweng Veterinary Grade APISingle-entity synthetic APIReference method
    Potency definitionMarker concentration and fingerprint area ratiosAssay of one molecule as percentage label claimHPLC/UV per registration dossier
    Native material formConcentrated aqueous extractCrystalline or amorphous powderVisual and particle size
    Drying behaviorRequires carrier adsorption or spray drying; heat-sensitive polyphenols presentDirect powder transfer; defined melting pointUSP <921> water determination
    Sterilization toleranceNot assumed to be terminally steam-sterilizable without marker lossOften withstands dry heat or steam under defined conditionsPh. Eur. 5.1.1 / 5.1.2
    Microbial controlNonsterile limits initially; bioburden reduction required for injectable useLow water activity usually restricts microbial proliferationUSP <61> / <62>

    Liquid-phase processing for oral solutions begins by diluting the API into a buffered aqueous vehicle at 20–30 °C. The native extract contains polysaccharides, tannins, and a small resinous fraction. If the vehicle pH falls below 3.5, the resinous fraction can precipitate and increase filter blinding. High-shear dispersion is used before transfer into a ring-layer or disc-type homogenizer, and the finished solution is passed through a 150 μm in-line strainer. Concentrate viscosity in some batches ranges from 50 mPa·s to 250 mPa·s at 25 °C; above 250 mPa·s, the liquid is warmed to 35–40 °C before pumping. Because the aqueous extract can support mold growth if unpreserved, antimicrobial effectiveness testing according to USP <51> is required for the final oral solution. Headspace oxygen should be maintained below 5%; if sodium metabisulfite is used, it is limited to 0.05–0.1 g/100 mL and must be confirmed compatible with the marker profile.

    For tablets, the wet extract must be converted into a free-flowing intermediate. Vacuum belt drying or spray drying is used; a typical spray-drying configuration operates at inlet air 160–180 °C and outlet temperature 70–85 °C. The dried product is hygroscopic. On production rotary tablet presses, final blend moisture above 4.0% is associated with picking and capping; therefore loss on drying by USP <731> is controlled at ≤3.5% before compression. Pre-blending with silicified microcrystalline cellulose at a 1:1 to 1:3 weight ratio reduces sticking. Tablet hardness is provisionally set at 60–90 N and friability below 1.0% after 100 revolutions, but the registered dossier is the controlling source for finished-product limits. Capsule filling requires the dried premix to pass a 600 μm screen; flow angle below 35° is maintained with 0.5–1.0% colloidal silicon dioxide.

    Process threshold matrix for converting the aqueous API into solid oral forms
    Unit operationEquipment typeCritical process rangeControl reference
    Carrier adsorptionVacuum paddle dryerJacket temperature 45–55 °C; vacuum -0.08 to -0.095 MPaLoss on drying
    Spray dryingRotary atomizerInlet 160–180 °C; outlet 70–85 °C; feed solids 25–35 g/100 gUSP <921>
    Dry blendingDouble-ribbon mixerCapacity 60–70%; time 15–20 min; tracer RSD ≤5.0%Mixer validation
    CompressionRotary tablet pressBlend LOD ≤3.5%; hardness 60–90 N; friability ≤1.0%USP <731>, USP <1216>
    Capsule fillingTamping pin or dosatorGranule moisture 2.0–5.0%; flow angle ≤35°USP <1174>
    Wet granulationHigh-shear mixerMoisture 40–46%; impeller 150–250 rpm; time ≤20 minIn-process LOD
    Fluid-bed dryingFluid-bed dryerInlet 60–70 °C; product 45–50 °C; final LOD ≤5.0%USP <731>

    When Saline, Acidic, or Injectable Vehicles Require De-pectinization and Prefiltration

    For injectable-grade intermediates, the native liquid cannot be expected to pass a sterilizing-grade 0.22 μm membrane without pretreatment. Pectinaceous material and high molecular weight polysaccharides foul membranes; on a production filtration skid using PVDF membrane, flux decline can exceed 60% within 15 min at 0.5 bar transmembrane pressure. A chilled precipitation step at 4–8 °C for 12–24 h is applied before kieselguhr filtration to reduce the colloidal burden. After de-pectinization, bioburden must be reduced to ≤10 CFU/100 mL before sterile filtration. Endotoxin is controlled by anion-exchange membrane chromatography or depyrogenated excipients; for injectable solutions, the release limit is commonly <0.5 EU/mL measured by Ph. Eur. 2.6.14. Terminal steam sterilization at 121 °C for 15 min is not assumed. Aseptic filling after membrane filtration is preferred; if terminal sterilization is required, the time–temperature exposure must be bracketed against marker recovery and pH stability. The injectable vehicle is buffered to pH 5.5–7.0; osmolality is adjusted to 280–320 mOsm/kg with sodium chloride or glycerol. Divalent metal salts at high concentration are avoided because polyphenols can form insoluble complexes.

    Premix and powder applications use a separate loading protocol. The liquid API is sprayed onto a carrier in a single-shaft paddle mixer; carrier temperature is maintained below 45 °C because frictional heating softens the dried extract. Sequential dilution in a double-ribbon mixer at 60–70% capacity for 15–20 min yields tracer coefficient of variation ≤5.0%. If the premix is intended for medicated feed, segregation is assessed by a 10 min tumbling test; acceptable segregation is less than 3.0% relative standard deviation. For granules, wet-massing with water at 8–12% w/w and extrusion through a 0.8 mm screen is followed by spheronization and fluid-bed drying. The dried granules are screened to 16–30 mesh (595–1190 μm).

    Granulation and Pelletization Process Boundaries for Heat-Sensitive Marker Compounds

    The aqueous extract is plasticized by residual water. When wet mass moisture is below 38%, die blockage and extruder torque increase; above 48%, the extrudate collapses and spheronization produces oversized agglomerates. A narrow working range of 40–46% moisture is therefore required. High-shear granulation with impeller speed 150–250 rpm and chopper speed 1,000–1,500 rpm should not exceed 20 min total time. In-process particle size is monitored by laser diffraction; D90 should remain below 1,500 μm. Fluid-bed drying with inlet temperature 60–70 °C and product temperature 45–50 °C preserves marker recovery in stability-conforming batches; above 75 °C, total flavonoid recovery can fall by more than 10% in some batches. Drying endpoint is set by loss on drying ≤5.0%. The dried system is hygroscopic and must be sealed in aluminum foil with a desiccant when ambient relative humidity exceeds 60%. Published data for this specific configuration is limited; therefore these parameters should be verified for each registration batch and each supplier lot.

    Compared with purified single compounds, the API leaves a colored residue on contact surfaces. Cleaning validation for blending and drying equipment requires swab recovery of marker compounds after cleaning, and visual inspection alone is insufficient. In multi-species feed mills, carryover is controlled by sequencing and purge batches because the colored extract provides a visible marker but can stain gaskets. These operational characteristics form the practical difference between the botanical API and colorless synthetic molecules used in comparable tablet, injection, capsule, powder, granule, premix, and solution matrices.

    Top